



Figure S2: Graphical representation of predicted magnitudes of increase in R- (blue) and S-oxazepam (orange) exposure with and without cannabinoid coadministration. AUCRs were calculated based on oral and inhaled doses (low, average, and high) of CBD and THC [20,57]. The dotted line represents the $\text{AUCR} \geq 1.25$ cut-off recommended by the FDA for a potential DDI [52].